Silverarc Capital Management »

Biodesix shares owned by Silverarc Capital Management

Quarter-by-quarter ownership of Biodesix (BDSX) shares owned by Silverarc Capital Management from 13F filings

Historical chart of Silverarc Capital Management investment in Biodesix

Tip: Access up to 7 years of quarterly data

All positions including Biodesix held by Silverarc Capital Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Biodesix by Silverarc Capital Management

Quarter filed Position value Share count Share price at filing
2024-06-30 $2.8M 1.8M 1.53

More positions owned by Silverarc Capital Management

Merus N V (MRUS)
Nuvalent Inc-a (NUVL)
Avidity Biosciences Ord (RNA)
Urogen Pharma (URGN)
Erasca (ERAS)
Insmed Call Call Option
Morphic Hldg (MORF)
Akero Therapeutics (AKRO)
Celldex Therapeutics Com New (CLDX)
Intra Cellular Therapies (ITCI)
Poseida Therapeutics I (PSTX)
Cogent Biosciences (COGT)
Insmed Com Par $.01 (INSM)
Alnylam Pharmaceuticals (ALNY)
Elutia Cl A Com (ELUT)

View all positions for Silverarc Capital Management

Top funds holding Biodesix

Telemark Asset Management
Soleus Capital Management
AIGH Capital Management
Birchview Capital
Sio Capital Management
Opaleye Management
Monashee Investment Management
Vanguard Group
Perceptive Advisors
Farallon Capital Management
Silverarc Capital Management
Essex Investment Management
Wells Fargo & Company
Geode Capital Management
Perkins Capital Management

View all funds holding Biodesix